Nexalin Technology Inc.

AI Score

XX

Unlock

1.92
-0.14 (-6.80%)
At close: Mar 28, 2025, 3:57 PM
2.05
7.25%
After-hours: Mar 28, 2025, 06:32 PM EDT

Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.

It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia.

The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.

It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia.

The company was incorporated in 2021 and is headquartered in Houston, Texas.

Nexalin Technology Inc.
Nexalin Technology Inc. logo
Country United States
IPO Date Sep 16, 2022
Industry Medical - Devices
Sector Healthcare
Employees 6
CEO Mark White

Contact Details

Address:
1776 Yorktown
Houston, Texas
United States
Website https://www.nexalin.com

Stock Details

Ticker Symbol NXL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001527352
CUSIP Number 65345B201
ISIN Number US65345B2016
Employer ID 27-5566468
SIC Code 3845

Key Executives

Name Position
Mark White President, Chief Executive Officer, Chief Financial Officer & Director
Carolyn Shelton Executive Vice President of Clinical, Quality & Regulatory Affairs and Chief Operating Officer
Dr. David Owens M.D. Chief Medical Officer & Director
John Patrick Claude Co-Founder and Director of Engineering & Development
Marilyn Elson Controller

Latest SEC Filings

Date Type Title
Mar 14, 2025 10-K Annual Report
Mar 13, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 10, 2025 5 Filing
Feb 06, 2025 8-K Current Report
Feb 05, 2025 4 Filing
Feb 04, 2025 4 Filing
Jan 30, 2025 S-1/A [Amend] Filing
Jan 29, 2025 5 Filing